从肿瘤精准医疗创新性临床试验探讨中医辨证论治科学性

详细信息    查看全文 | 推荐本文 |

英文篇名：Discussion on Scientificalness of TCM Syndrome Differentiation and Treatment Based on Innovative Clinical Trials of Tumor Precision Medicine 作者：眭瑞卿 ; 朱超林 英文作者：SUI Ruiqing;ZHU Chaolin;Nanjing University of Chinese Medicine;Jiangsu Province Hospital of TCM; 关键词：篮子试验 ; 雨伞试验 ; 辨证论治 ; 肿瘤 ; 证候 ; 基因 英文关键词：basket trial;;umbrella trial;;TCM syndrome differentiation and treatment;;tumor;;syndromes;;genes 中文刊名：XXYY 英文刊名：Chinese Journal of Information on Traditional Chinese Medicine 机构：南京中医药大学;江苏省中医院; 出版日期：2019-04-10 出版单位：中国中医药信息杂志 年：2019 期：v.26;No.297 基金：第四批全国中医优秀人才研修项目(2017年);; 全国名老中医药专家传承工作室建设项目(2011年) 语种：中文; 页：XXYY201904001 页数：4 CN：04 ISSN：11-3519/R 分类号：6-9

摘要

"篮子试验"(basket trial)及"雨伞试验"(umbrella trial)是肿瘤精准医疗框架下开展的创新性临床试验,蕴含中医辨证论治的精神实质——"同病异治"和"异病同治",体现了中医辨证论治的科学性。证候及基因是中西医辨治疾病的不同途径,有异曲同工、殊途同归之妙。本文提出将证候与基因的内在联系具体化,有助于进一步挖掘中医肿瘤辨证论治与肿瘤精准医疗间的深层联系,使中医药更好地服务于临床,同时为中医辨证论治科学性提供理论依据。
        "Basket trial" and "umbrella trial" are innovative clinical trials carried out under the framework of precision medicine, which contains the essence of TCM syndrome differentiation and treatment — "different treatments for the same disease" and "the same treatment for different diseases", specifically reflects the scientificalness of TCM syndrome differentiation and treatment. Syndromes and genes are different ways of treating diseases in TCM and Western medicine, which have the wonder of using different approaches to achieve equally satisfactory results. This article proposed to clarify the internal relationship between syndromes and genes, and help to further explore the deep connection between TCM syndrome differentiation and treatment for tumor and tumor precision medicine, so that TCM can better serve the clinic, and provide a theoretical basis for scientificalness of TCM syndrome differentiation and treatment.

引文

[1]《胃肠病学和肝病学杂志》编辑部.2017年国家启动“精准医学计划”[J].胃肠病学和肝病学杂志,2017,26(1):7-16.
    [2]邵小钧,席庆.精准医疗--肿瘤诊治的新模式[J].现代肿瘤医学,2016,24(4):675-677.
    [3]KRETZLER M,SEDOR J R.Introduction:Precision medicine for glomerulardisease:The road forward[J].Semin Nephrol,2015,35(3):209-211.
    [4]KLAUSCHEN F,ANDREEFF M,KEILHOLZ U,et al.The combinatorial complexity of cancer precision medicine[J].Oncoscience,2014,1(7):504-509.
    [5]吴一龙.精准癌医学:走向未来的路[J].循证医学,2015,15(1):1-2.
    [6]梅志刚,谭凌菁.从辨证论治看中医在我国精准医疗计划中的作为[J].中华中医药杂志,2016,31(10):3887-3890.
    [7]俞悦,周爱萍,曾益新.HER2阳性胃癌的治疗研究进展[J].中国肿瘤临床,2017,44(2):59-63.
    [8]王绍钧,王锐,朱冬波.实体瘤靶向药物的研究进展[J].中国药房,2017,28(8):1149-1152.
    [9]HYMAN D M,PUZANOV I,SUBBIAH V,et al.Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J].New England Journal of Medicine,2015,373(8):726-736.
    [10]National Cancer Institute.Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors,lymphomas,or multiple myeloma(The MATCH Screening Trial)[EB/OL].(2015-06-08)[2017-07-17].https://www.clinicaltrials.gov/ct2/show/NCT02465060?cond=NCT02465060&rank=1.html.
    [11]陆兵.Ⅳ期肺腺癌初治患者的中医证型及临床特点分析[D].北京:北京中医药大学,2011.